Biological age and biomarker diagnostics
Establishing what ageing looks like in an individual body, and how reliably that can be measured.
- Multi-omic and inflammatory panels
- Organ-level functional measures
- Longitudinal baselines
Circularity Labs
The life-expansion R&D engine.
Circularity Labs is where our research questions become testable programmes. It is deliberately small, deliberately cautious, and built around measurement before intervention.
Concept stageSix programmesSafety-led design
The lab
Researching life expansion, one verifiable question at a time.
We are not claiming to have extended a human lifespan, and we will not. What we are doing is building the capability to ask better questions: what ageing is, where it can be interrupted, and what evidence would justify going further.
Each programme is designed to fail safely and in public. Where an approach carries serious risk — cell identity loss, tumourigenicity, immune response — the risk is part of the research plan, not a footnote.
Programmes
Six research programmes.
Senolytics and cellular clean-up
Researching whether the burden of senescent cells can be reduced selectively, without disturbing healthy tissue.
- Selectivity and off-target effects
- Tissue-specific response
- Combination approaches
Epigenetic and partial reprogramming research
Exploring transient, controlled changes in cell state — with explicit limits against identity loss and tumour risk.
- Transient expression windows
- Cell-identity safeguards
- Reversibility studies
AI-driven protein and therapeutic design
Using predictive models to shorten the path from hypothesis to something a laboratory can actually test.
- Structure and binding prediction
- Candidate triage
- Model uncertainty, stated openly
Regenerative medicine, organ engineering and gene-editing research
Tissue repair, ex-vivo organ approaches and precise editing — areas where the safety bar is highest.
- Base editing precision
- Ex-vivo organ therapy
- Bioprinted tissue concepts
Precision prevention with continuous monitoring
Turning continuous signal into earlier, gentler intervention — prevention treated as a research discipline.
- Wearable and home measurement
- Early-warning models
- Clinician-in-the-loop review
Try the model
An illustrative biological age estimator.
Our first programme asks how reliably ageing can be measured in an individual body. Until validated panels exist, here is a deliberately simple arithmetic model — the everyday factors we would want to measure properly, weighted openly and shown in full.
Your inputs
Illustrative result
40.0years
in line with your chronological age. Modelled from the inputs on the left only.
- Sleep0.0 yrs7 hours a night
- Activity0.0 yrs3 active days a week
- Resting heart rate0.0 yrs62 bpm
- Stress0.0 yrs4 of 10
- Smoking0.0 yrsnever smoked
This is an illustration, not a test. It applies fixed weights to five self-reported factors to show how a model like this behaves — it is not a validated biological-age measurement, a medical assessment or advice about your health. Real work in this area requires clinical-grade panels, longitudinal data and ethics review, which we do not yet offer.
Horizon Map
Four horizons, in order of risk.
A map of the research directions we find worth pursuing, sequenced by how much has to be proven before the next step is responsible.
Horizon Map
Four illustrative research horizons. Select a stage to explore it.
Stage 1
Cellular clean-up and resets
The earliest horizon: reducing the burden of damaged and senescent cells, and testing whether controlled resets of cell state can be made safe and reversible.
- Senolytics — compounds that selectively target senescent cells, researched for their effect on tissue function.
- Plasma exchange — exploring how circulating factors influence repair signalling.
- Partial reprogramming — transient epigenetic signals, studied with explicit tumour-risk limits.
Illustrative research horizons, not clinical claims or forecasts. Nothing described here is available as a treatment, and none of these approaches is proven in humans.
Company roadmap
Where we are, and what comes next.
01Current stage
Concept
Defining the research questions, governance and founding team.
02In progress
Founding Partners
Forming academic, clinical and investment partnerships.
03Planned
Pilot Research
Small, well-instrumented studies with pre-registered endpoints.
04Planned
Clinical Collaborations
Partner-led clinical research, subject to ethics and regulatory approval.
Collaborate
Research partners shape what we build first.
If your group works on ageing biology, biomarkers or regenerative medicine, we would like to hear from you.